These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23529930)

  • 21. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
    Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
    PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
    Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
    Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
    Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
    Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
    Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
    J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
    Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
    Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
    Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
    Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
    Zhang Q; Padi SK; Tindall DJ; Guo B
    Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
    Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
    Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.
    Li Z; Wang Y; Qiu J; Li Q; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Yang J; Cheng J
    Oncotarget; 2013 Dec; 4(12):2532-49. PubMed ID: 24345883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.
    Puppe J; Drost R; Liu X; Joosse SA; Evers B; Cornelissen-Steijger P; Nederlof P; Yu Q; Jonkers J; van Lohuizen M; Pietersen AM
    Breast Cancer Res; 2009; 11(4):R63. PubMed ID: 19709408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
    Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
    Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
    Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
    Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
    Lv YF; Yan GN; Meng G; Zhang X; Guo QN
    Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
    Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
    J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.